Literature DB >> 3456620

Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog.

J Mehta, T Wargovich, W W Nichols.   

Abstract

Platelet-activating factor (PAF), modulates vascular tone by influencing prostaglandin release and vascular permeability. To determine its coronary effects we administered PAF (0.3 to 10 ug) into the left main coronary artery of anesthetized dogs with patent left circumflex (LCx) and narrowed left anterior descending (LAD) coronary arteries. PAF produced an initial increase followed by a decrease in coronary blood flow (CBF). The CBF increase was greater in the patent LCx than in the narrowed LAD, but the decrease was similar in both. These effects of PAF on CBF were dose-dependent, and associated with an increase in prostacyclin and thromboxane A2 metabolites. To examine the contribution of prostaglandin release in coronary effects of PAF, dogs were pretreated with indomethacin (5 mg/kg) followed by administration of PAF. In indomethacin-pretreated animals, the coronary effects of PAF were significantly attenuated. This study shows that PAF has biphasic effects on CBF in the normal coronary artery, but the major effect in the narrowed coronary is decrease in CBF. These effects of PAF can be attenuated by prior treatment of dogs with indomethacin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456620     DOI: 10.1016/0262-1746(86)90166-6

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  8 in total

1.  Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.

Authors:  J R Fletcher; A G DiSimone; M A Earnest
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

2.  Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart.

Authors:  W M Hu; P C Choy; R Y Man
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

3.  Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart.

Authors:  W Hu; A A Kinnaird; R Y Man
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

4.  Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; L Tuomisto; T J Metsä-Ketelä; H Vapaatalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

5.  Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit.

Authors:  M M Nieminen; M Hill; C G Irvin
Journal:  Agents Actions       Date:  1991-03

Review 6.  The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging.

Authors:  C Kroegel; C Kortsik; N Kroegel; H Matthys
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

7.  Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart.

Authors:  W M Hu; R Y Man
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 8.  Platelet-activating factor in cardiovascular stress situations.

Authors:  R Rabinovici; T L Yue; G Feuerstein
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.